CDH4 and osteosarcoma: The transcriptional level of CDH4 may serve as an effective diagnostic and prognostic biomarker for renal cell carcinoma patients (Zhou et al., 2020), as it is a novel determinant of osteosarcoma tumorigenesis and metastasis (Tang et al., 2018).